Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
RESEARCH TOOLSreports
NAMS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.06 - $27.29
Previous CloseN/A
Volume118.30K
Average Volume (3M)1.08M
Market Cap
$1.92B
Enterprise Value$1.66B
Total Cash (Recent Filing)$771.74M
Total Debt (Recent Filing)$448.00K
Price to Earnings (P/E)―
Beta1.78
Next Earnings
May 07, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding109,817,810
10 Day Avg. Volume508,344
30 Day Avg. Volume1,075,374
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)79.94
Price to Cash Flow (P/CF)-52.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit36.43
Enterprise Value/Ebitda-6.94
Forecast
1Y Price Target
$43.00Price Target Upside145.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
NewAmsterdam Pharma Company News
PremiumCompany Announcements
NewAmsterdam Pharma Appoints Adele Gulfo to Board
PremiumCompany Announcements
NewAmsterdam Pharma’s 2024 Financial Results and Clinical Progress
---
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company reported a strong cash position of $834.2M, which is believed to amply fund operations through the CVOT top-line in 2H26 and drive launch prep for obi in the US.
Regulatory DevelopmentsA new executive order could extend small molecule exclusivity from 9 to 13 years, aligning it with biologics, which would particularly benefit NAMS by delaying Medicare price negotiations.
Strategic InterestNAMS could see significant strategic interest from pharma in the future, driven by factors like patent exclusivity until 2043 and potential for mass market combinations.
Bears Say
Data Catalyst TimelineThe next significant data catalyst is not expected until PREVAIL CVOT.
Market ComparisonThe market opportunity for NewAmsterdam is not seen as being meaningfully altered by AstraZeneca's results.
Research And Development CostsPrice target moves to $42 from $46 to reflect model updates with higher than expected R&D in 2025.
---
Ownership Overview
16.67% Insiders
7.62% Mutual Funds
2.64% Other Institutional Investors
72.21% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $14.06 and its highest was $27.29 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
NewAmsterdam Pharma Company’s market cap is $1.92B.
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is May 07, 2025 which is in 10 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Feb 26, 2025. The company reported -$0.93 earnings per share for the quarter, missing the consensus estimate of -$0.486 by -$0.444.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -0.5.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 109,817,810 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.93 in its last earnings report, missing expectations of -$0.486. Following the earnings report the stock price went up 10.235%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Currently, no hedge funds are holding shares in NAMS
---
NewAmsterdam Pharma Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (145.43% Upside)
$43.00 (145.43% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 4.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Company Description
NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
---
NAMS Stock 12 Month Forecast
Average Price Target
$43.00
▲(145.43% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Harmony Biosciences Holdings
―
Recursion Pharmaceuticals
―
Metsera, Inc.
―
Best Analysts Covering NAMS
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+21.64%
reiterated a buy rating 12 days ago
Copying Dennis Ding's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +21.64% per trade.
---